Safety and PK Multi-dose Study of TAF/EVG Vaginal Insert
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
MATRIX-001 will examine the safety, PK, modeled PD, and acceptability of inserts containing
the combination of TAF and EVG applied vaginally, daily for 3 days, then every other day for
14 days. The inserts are ultimately intended to be the basis of an event-driven, on-demand
method for prevention of HIV and HSV sexual infection.
Phase:
Phase 1
Details
Lead Sponsor:
Eastern Virginia Medical School
Collaborators:
Centre for the AIDS Programme of Research in South Africa CONRAD Kenya Medical Research Institute United States Agency for International Development (USAID) University of Pittsburgh